ClinicalTrials.gg
WithdrawnNCT02719132FLORAUpdated May 20, 2016

Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

A Phase 4 interventional study of Dapagliflozin and Metformin in Diabetes Mellitus Type 2, sponsored by AstraZeneca. Withdrawn. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-05-20.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
179th of 180
0 · median 82
Started
2016
with 18 others
Phase 4
77 of 180
7 open now
Registered
78th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 179th largest by enrollment, is one of 19 that started in 2016, is one of 77 in phase 4, and was the 78th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a multicenter, randomised, open-label, crossover, 2-period comparative phase IV study.

The primary objective is to compare the effect of dapagliflozin 10 mg once daily in combination with metformin at a daily dose of ≤1,500 mg vs. metformin monotherapy with dose titrated up to 2,500 mg/day on the overall quality of life, obesity-specific quality of life and treatment satisfaction in patients with type 2 diabetes.

Read the detailed description

The study will comprise the following phases: Screening, Treatment Period 1 and Treatment Period 2.

After screening examinations and assessments, all patients enrolled will be randomly assigned in equal proportion (1:1) to either study arm:

Arm 1:

  • Patients will take dapagliflozin 10 mg in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks during Treatment Period 1
  • Patients will be on metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks during Treatment Period 2

Arm 2 (the same treatment phases in reverse order):

  • Patients will be on metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks during Treatment Period 1
  • Patients will take dapagliflozin 10 mg in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks during Treatment Period 2 Following the randomisation procedure, patients will receive investigational products at each visit as scheduled by Treatment Period 1. After the Randomisation Visit (Visit 2), the patient should attend the study centre for Visits 3, 4, and 5 (Day 28, Day 86, and Day 168, respectively) for efficacy and safety assessments. At Visit 5 (Day 168), the patient will receive investigational products as required by Treatment Period 2. Further Visits 6, 7 and 8 will be scheduled on Day 196, Day 252, Day 336, respectively.
03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • Diabetes Mellitus type 2, dapagliflozin, quality of life
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study patients should fulfil ALL the criteria listed below:

  1. A voluntary form for participation in the study signed by the patient prior to any study-specific procedures
  2. Male and female patients of 18-74 years of age
  3. Diagnosed type 2 diabetes
  4. Therapy with metformin at a stable dose ≤1,500 mg/day for at least 8 weeks before enrolment
  5. >7.0% and ≤10% at the Screening Visit
  6. C-peptide ≥1.0 ng/ml at the Screening Visit
  7. ≤45.0 kg/m² at the Screening Visit
  8. For women of - use of reliable methods
  9. Ability to complete study-specific procedures
  10. Ability to complete questionnaires

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes
  2. Diabetic ketoacidosis at Screening
  3. and/or ALT > 3 × at Screening
  4. Total serum > 34.19 μmol/l at Screening
  5. Decompensated diabetes mellitus ( >10% at Screening)
  6. Patients with moderate to severe renal impairment ( \<60 ml/min or \<60 ml/min/1.73 m2 at Screening) or terminal renal insufficiency
  7. Severe concomitant diseases or severe cardiovascular, renal, hepatic, hematologic, endocrine, mental or rheumatic pathology
  8. within 5 years before enrolment
  9. Acute (including viral and infectious) diseases within 1 month before the Screening Visit.
  10. Development of severe acute diseases during the study which significantly affect the benefit/risk ratio for the subject or affecting study efficacy/safety assessment criteria
  11. History of acute myocardial infarction or stroke within 6 months before the Screening Visit or during the study. Heart failure ( III-IV)
  12. Treatment with drugs affecting glucose homeostasis (e.g., systemic glucocorticosteroids) within 3 months before to the Screening Visit.
  13. For women of - a positive pregnancy test or the patient is breast-feeding or planning pregnancy during the study
  14. History of and C or
  15. Individual to any component of the product (dapagliflozin)
  16. Treatment with sodium-dependent glucose cotransporter inhibitors (SGLT2) has been administered within 3 months prior to enrolment or is planned during the study.
  17. Loop diuretics have been administered for 3 months before the Screening Visit or are planned during the study.
  18. Hereditary lactose intolerance, lactase deficiency and glucose-galactose malabsorption
  19. The patient is unable to follow study procedures and attend the study centre for scheduled study visits or is going to relocate within the protocol-specific timelines
  20. The patient is a subject of other studies within 3 months before enrolment
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm 1

    Arm 1 - therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks (Treatment Regimen 1) followed by metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks (Treatment Regimen 2)

    Drug: Dapagliflozin · Drug: Metformin

  • Active comparator
    Arm 2

    Arm 2 - metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks (Treatment Regimen 2) followed by therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks (Treatment Regimen 1)

    Drug: Dapagliflozin · Drug: Metformin

Interventions

  • Dapagliflozin, 10 mg

    Also known as: Forxiga

  • Metformin, up to 2500 mg

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. Composite endpoint including quality of life score

    Change in the overall quality of life, obesity-specific quality of life and treatment satisfaction in the course of the therapy by the end of each 24-week treatment period compared to the quality of life, obesity-specific quality of life and treatment satisfaction at baseline.

    Time frame: 48 weeks

Secondary outcomes

  1. Change in HbA1c level

    Change in HbA1c level will be assessed as mean change in the course of the treatment compared to baseline.

    Time frame: 48 weeks

  2. Change in body weight

    Change in body weight will be assessed as mean change in body weight, mean percentage change in body weight and mean change in body mass index compared to baseline and as proportion of patients with body weight decreased by ≥5% during the treatment phase.

    Time frame: 48 weeks

  3. Change in waist circumference

    Change in waist circumference will be assessed as mean change and mean percentage change in waist circumference during the treatment phase compared to baseline.

    Time frame: 48 weeks

  4. Change in fasting plasma glucose

    Change in fasting plasma glucose will be assessed as mean change in fasting plasma glucose during the treatment phase compared to baseline.

    Time frame: 48 weeks

  5. Proportion of patients

    Proportion of patients who achieved therapeutic glycaemic response (HbA1c ≤7%).

    Time frame: 48 weeks

Other outcomes

  1. ECG variables

    ECG records including the following variables: heart rate (beats per minute), QT (msec), QTcB (msec), sinus heart rate (yes/no)

    Time frame: 48 weeks

  2. number of episodes of hypoglycaemia and ketoacidosis

    number of episodes of hypoglycaemia and ketoacidosis

    Time frame: 48 weeks

  3. change in glomerular filtration rate

    change in glomerular filtration rate compared to baseline at Screening

    Time frame: 48 weeks

  4. laboratory values changes

    laboratory values (ALT, AST, total bilirubin, and creatinine)

    Time frame: 48 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2016
First posted
Mar 25, 2016
Start
Jul 2016
Primary completionEst.
Nov 2017
CompletionEst.
Nov 2017
Last update
May 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02719132
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 25, 2016
Start date
Jul 2016
Primary completion
Nov 2017 (estimated)
Completion
Nov 2017 (estimated)
Last update
May 20, 2016

Study contacts

Marina Shestakova, Professor
principal investigator · Russian Federal Research Endocrinology center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion